Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Haidian 100142, Beijing, China.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Medical Record Statistics, Peking University Cancer Hospital and Institute, Haidian 100142, Beijing, China.
Aging (Albany NY). 2021 Mar 26;13(7):10225-10239. doi: 10.18632/aging.202782.
Typically, peripheral T-cell lymphoma (PTCLs) prognosis is estimated using overall survival before treatment. However, these estimates cannot show how prognosis evolves with the changing hazard rate over time. Patients (n = 650) with newly diagnosed PTCLs were enrolled retrospectively. After a median follow-up of 5.4 years, angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) and NK/T cell lymphoma had initially lower 3-year conditional overall survival (COS3; i.e., the 3-year conditional overall survival was defined as the probability of surviving an additional 3 years) and higher hazards of death (26-44.3%). However, after 2 years, the COS3 increased and the death risk decreased over time, whereas anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma constantly had a lower risk over time (0-19.5%). For patients with complete remission after initial treatment, prognosis varied by histological subtypes, with PTCL, NOS having a negative impact. Our data suggested that the risk stratification using the International Prognostic Index might not accurately predict the COS3 for survivors of PTCLs. The COS3 provided time-dependent prognostic information for PTCLs, representing a possible surrogate prognosis indicator for long-term survivors after systemic chemotherapy.
通常,外周 T 细胞淋巴瘤(PTCL)的预后是在治疗前使用总生存时间来估计的。然而,这些估计并不能显示随着时间的推移,风险率的变化如何影响预后。回顾性招募了 650 名新诊断为 PTCL 的患者。中位随访 5.4 年后,血管免疫母细胞性 T 细胞淋巴瘤、外周 T 细胞淋巴瘤、非特指型(PTCL-NOS)和 NK/T 细胞淋巴瘤最初具有较低的 3 年条件总生存(COS3,即 3 年条件总生存被定义为额外存活 3 年的概率)和更高的死亡风险(26-44.3%)。然而,2 年后,COS3 增加,死亡风险随时间降低,而间变性淋巴瘤激酶阳性间变性大细胞淋巴瘤的风险始终随时间降低(0-19.5%)。对于初始治疗后完全缓解的患者,预后因组织学亚型而异,PTCL-NOS 具有负面影响。我们的数据表明,国际预后指数的风险分层可能无法准确预测 PTCL 患者的 COS3。COS3 为 PTCL 提供了随时间变化的预后信息,是全身化疗后长期幸存者的可能替代预后指标。